801303-33-3

Basic information

• Product Name: 4-BROMO-2-FLUORO-N-METHOXY-N-METHYLBENZAMIDE
• Synonyms: 4-BROMO-2-FLUORO-N-METHOXY-N-METHYLBENZAMIDE;N-Methoxy-N-methyl 4-bromo-2-fluorobenzamide;BenzaMide, 4-broMo-2-fluoro-N-Methoxy-N-Methyl-
• CAS NO: 801303-33-3
• Molecular Formula: C₉H₉BrFNO₂
• Molecular Weight: 262.08
• Mol File: 801303-33-3.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 4-BROMO-2-FLUORO-N-METHOXY-N-METHYLBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-FLUORO-N-METHOXY-N-METHYLBENZAMIDE(801303-33-3)
• EPA Substance Registry System: 4-BROMO-2-FLUORO-N-METHOXY-N-METHYLBENZAMIDE(801303-33-3)

Safety Data

• Hazardous Substances Data: 801303-33-3(Hazardous Substances Data)

Usage

General Description

4-BROMO-2-FLUORO-N-METHOXY-N-METHYLBENZAMIDE is a chemical compound with the molecular formula C9H9BrFNO2. It is a synthetic organic compound that belongs to the benzamide class and contains bromine, fluorine, nitrogen, oxygen, hydrogen, and carbon atoms. 4-BROMO-2-FLUORO-N-METHOXY-N-METHYLBENZAMIDE is commonly used in pharmaceutical research as a building block for the synthesis of potential drug candidates. Its structure and properties make it suitable for medicinal chemistry applications and it has been studied for its potential biological activities. However, specific information on its uses and potential effects is not widely available to the public.

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 151982-51-3 4-bromo-2-fluorobenzoyl chloride 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 259750-61-3 1-(4-bromo-2-fluorophenyl)propan-1-one 
• 801303-34-4 3-fluoro-4-(2-methylpropionyl)benzoic acid 

Relevant articles and documents

Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists

A series of N-methoxyamide derivatives was identified and evaluated as GPR119 agonists. Several N-methoxyamides with thienopyrimidine and pyridine scaffolds showed potent GPR119 agonistic activities. Among them, compound 9c displayed good in vitro activity and potency. Moreover, compound 9c lowered glucose excursion in mice in an oral glucose tolerance test and increased GLP-1 secretion in intestinal cells.

DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS

The present invention is directed to dihydropyrazolopyrimidinonecompounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

ANTIDIABETIC BICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.